FOUNDER PROFILE

Dr. Mark Kotter

Dr. Mark Kotter

Dr. Mark Kotter

Mark Kotter is the Austrian co-founder at Dutch cell-based meat startup Meatable, the first to use pluripotent stem cells and claim a highly scalable culture technology, which was developed by Kotter prior to founding the startup in 2018. He is also founder at his biotech startup, bit.bio, which is based in Cambridge, UK, since 2016, where he applies his cellular technological innovation to human stem cell research and has raised investments totaling $42m. His main full-time position is at the University of Cambridge, where he has worked since 2009. He has spent more than five years as a clinician-scientist in stem cell research and was previously a lecturer in neurosurgery. Kotter also lectures at Paris Descartes University and is a team leader at the UK’s National Institute for Health Research’s Brain Injury MedTech Co-operative. He also founded Myelopathy.org to raise awareness of cervical myelopathy. 

His past positions were as a research group leader at the Max Planck Institute for Experimental Medicine for one year, and for two years spent at the Medical University of Vienna. 

Kotter holds two doctorates; one in philosophy from the University of Cambridge and the other in medicine from the University of Graz in Austria. Kotter also holds a master’s in philosophy from the University of Cambridge.

Limited Reading

The rest of the content is only available if you are logged in.

Limited Reading

RELATED INSIGHTS

Gift This Article

The gift link can be opened by one recipient only.

You have 19 gift credits left this month

Your payment was not successful.

Please make sure you have entered your payment details correctly. Or try again in a few moments.

small logo

The discount code you entered is invalid

Please make sure you have entered your discount code correctly. Or try again in a few moments.

Download successful.

Your sample has been sent. Please check your email.

By accessing and using www.compasslist.com and all pages within the domain (the “Website”), You accept and agree to have read, understood, accepted and agreed to be bound by the Terms of Use and Privacy Policy in full. If you disagree with all or any part of these Terms of Use and Privacy Policy, please do not use or continue any further use of this website. You acknowledge that you are aware that this Website contains an archive of existing content as at 31 December 2021 and is not being actively managed. We are under no obligation to update the content on this Website and, accordingly, no new content or articles will be posted to the Website after 31 December 2021.